NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Medical Devices · USD

Haemonetics Corporation (HAE) Stock Analysis

Haemonetics Corporation (HAE) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

HAE

$117.11

−$1.10 (−0.93%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HAE with… →

HAE Key Statistics

As of Oct 21, 2026
Trading
Open
$117.49
Previous Close
$118.21
Day's Range
116.67–119.12
52-Week Range
48.98–123.77
Volume
837.35K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.61
Valuation
Market Cap
$5.33B
P/E Ratio
56.57
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
20.27
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.87
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.94
EPS (ttm)Profit attributable to each share over the last twelve months.
2.07
Financials (FY)
Revenue (FY)
$1.33B−1.97%
Net Income (FY)
$97.31M−41.97%
Profit marginThe share of revenue left as profit after all costs and taxes.
7.12%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.50M
1-Year Return
+128.78%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
731.86K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HAE closed at $117.11, +128.78% over 1 year.

Haemonetics Corporation (HAE) has a market capitalization of $5.33B.

In fiscal 2025, HAE reported revenue of $1.33B.

HAE Stock Return by Calendar Year

Haemonetics Corporation (HAE) 10-year return: what $10,000 became

1 year
$10,000 $22,878
+128.78%
5 years
$10,000 $16,349
+63.49%
10 years
$10,000 $34,223
+242.23%

If you had invested $10,000 in Haemonetics Corporation (HAE) 10 years ago, at the close on October 21, 2016, it would have been worth $34,223 at the close on October 21, 2026: +242.23% in total, +13.09% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+46.11%
2025+2.65%
2024−8.69%
2023+8.72%
2022+48.28%
2021−55.33%
2020+3.35%
2019+14.84%
2018+72.26%
2017+44.48%
2016 (partial year)+13.72%

As of October 21, 2026.

HAE Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$1.33B$97.31M7.3%
2024$1.36B$167.68M12.3%
2023$1.31B$117.56M9.0%
2022$1.17B$115.40M9.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.33B$787.59M$241.40M$97.31M7.3%
2024$1.36B$748.96M$201.19M$167.68M12.3%
2023$1.31B$691.55M$175.30M$117.56M9.0%
2022$1.17B$615.10M$155.65M$115.40M9.9%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

HAE Valuation vs Medical Devices Median

Median of 145 stocks
MetricHAEMedical Devices medianvs median
P/E56.5727.08109% above
P/S ratio3.942.5356% above
Profit margin7.12%−14.78%21.9 pts above

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Haemonetics Corporation (HAE) carries a market capitalisation of $5.33B. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 3,009 employees.

The most recent close on file for HAE is $117.11, dated October 21, 2026. That is −$1.10 (−0.93%) against the previous close. The 52-week range on file runs from $48.98 to $123.77. The latest close sits 139.1% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.33B. That is −1.97% against the prior fiscal year, when revenue was $1.36B. The same year closed with net income of $97.31M. That is −41.97% against the prior fiscal year. Profit margin runs at 7.12%. That is 21.9 percentage points above the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to 2.07.

Across the 4 fiscal years on file, revenue moves from $1.17B in 2022 to $1.33B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 56.57 times earnings. That is 108.9% above the Medical Devices median of 27.08. The forward P/E on file is 20.27. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.87. The price-to-sales ratio is 3.94. On price-to-sales that is 55.79% above the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

Over the trailing twelve months the total return is +128.78%. Across 10 years the annualized return works out at +13.09%. The reported beta is 0.61. Daily returns over the trailing 10 years annualize to a volatility of 40.62%.

Growth & Income

The record shows no dividend for HAE.

So far in 2026 the total return is +46.11%. Across the complete calendar years on file, 2018 returned +72.26% and 2021 returned −55.33%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Haemonetics Corporation (HAE) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Haemonetics Corporation HAE $5.33B 56.6
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Haemonetics Corporation trades at a P/E of 56.6.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Haemonetics Corporation

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Visit website →